FDA mirvetuximab soravtansine coverage for business development, investment, and market access teams
The FDA has approved Elahere for expanded use in patients with platinum-resistant ovarian cancer, marking a significant advancement in treatment options.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
